Vaxart, Inc.

Vaxart, Inc. is a clinical-stage biotechnology company that develops oral recombinant vaccines. The company's primary focus is on its proprietary oral vaccine platform called Vector-Adjuvant-Antigen Standardized Technology ("VAAST"). Vaxart is developing prophylactic vaccine candidates for infectious diseases such as norovirus, coronavirus (including SARS-CoV-2, which causes COVID-19), and influenza. Additionally, the company has generated preclinical data for a therapeutic vaccine candidate aimed at cervical cancer and dysplasia caused by human papillomavirus ("HPV"). Vaxart's oral tablet vaccine candidates are designed to produce broad and lasting immune responses, including systemic, mucosal, and T cell responses, which may offer enhanced protection against certain infectious diseases and potential clinical benefits for some cancers and chronic viral infections like HPV. These tablet vaccines are also intended to provide a more efficient and convenient administration method, improve patient acceptance, and reduce distribution challenges, potentially enhancing the effectiveness of vaccination campaigns. The company's platform technology uses a vector-based approach, where a virus acts as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. Vaxart was originally incorporated in California in March 2004 as West Coast Biologicals, Inc., reincorporated in Delaware in July 2007 as Vaxart, Inc. ("Private Vaxart"), and completed a reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018.